Am J Cancer Res 2026;16(2):660-662
www.ajcr.us /ISSN:2156-6976/ajcr0172073

Erratum
Molecular determinants of response to PI3K/AKT/mTOR and KRAS pathways inhibitors in NSCLC cell lines: Am J Cancer Res. 2020; 10(12): 4488-4497

Alice Iezzi*, Elisa Caiola*, Marika Colombo, Mirko Marabese, Massimo Broggini

*Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. *Equal contributors.*

Received February 12, 2026; Accepted February 21, 2026; Epub February 25, 2026; Published February 28, 2026

The published version of our article contains some errors in **Figures 3**, **5** that do not affect the final findings or conclusions, and we hereby publish the corrections. We sincerely apologize for these unintentional errors, which arose from carelessness during data acquisition and image preparation. The new versions of **Figures 3** and **5** are shown below.

Address correspondence to: Massimo Broggini, Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via Mario Negri 2, 20156 Milan, Italy. E-mail: massimo.broggini@marionegri.it

https://doi.org/10.62347/KXSN5341



Figure 3. Representative western blot analysis showing the ability of the four PI3K/mTOR pathway inhibitors to modify the phosphorylation of proteins involved in the pathways transduction in eight NSCLC cell lines. Proteins were extracted 0, 6 and 24 hours after treatment start. Cells were treated with a concentration corresponding to the IC50 of the drug determined in the most sensitive cell line. The different cell lines were run on different gels.



Figure 5. Representative western blot analysis showing the ability of MEK-162 and SCH772984 to modify the phosphorylation of ERK and other proteins as indicated in the figure in eight cell lines 6 and 24 hours after treatment start. Cells were treated with a concentration corresponding to the IC50 of the drug determined in the most sensitive cell line. The different cell lines were run on different gels.